Drugs / CC-EIEs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03362619 | Jun 2026 → Dec 2029 expected | cervical cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-EIEs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03362619 ↗ |
| Known as | EIEs | “Autologous cervical cancer specific engineered immune effectors (EIEs)” NCT03362619 ↗ |
| Modality | Cell therapy | “engineered immune effectors including cytotoxic T lymphocytes” NCT03362619 ↗ |
| Route | Intravenous | “via IV” NCT03362619 ↗ |